NeuroSense CEO updates shareholders on PARAGON financing, Canada filing, Nasdaq issue

NeuroSense Therapeutics Ltd. released a shareholder letter from CEO Alon Ben-Noon on August 13, 2026, addressing the status of its pivotal Phase 3 PARAGON study of PrimeC in ALS.

The FDA has cleared NeuroSense to initiate PARAGON, which is expected to enroll approximately 300 participants, primarily in the United States.¹ However, the company said the study requires substantial financial resources, and securing that funding has taken longer than originally anticipated.¹ Ben-Noon wrote that the company is pursuing multiple funding avenues at once, including talks with pharmaceutical partners, investors, other financing sources, and non-dilutive grant funding, and said it believes the quality of the financing matters.¹ In April 2026, Ben-Noon and CFO Or Eisenberg each invested $200,000 in NeuroSense, for an aggregate of $600,000 together with an existing investor.¹

Separately, the company is pursuing a regulatory path in Canada based on existing data. Following discussions with Health Canada, including a pre-NDS process, NeuroSense is preparing a New Drug Submission for PrimeC, which it currently expects to submit in December 2026.¹ The planned submission builds on clinical and biomarker data from the Phase 2b PARADIGM study.¹

On listing compliance, NeuroSense said it is working to address Nasdaq continued-listing deficiencies, with its most immediate focus on the minimum bid price requirement.¹ Shareholders will vote on a proposal authorizing the board to carry out a reverse share split, at a ratio between 1-for-4 and 1-for-40, if needed to regain compliance.¹ The company said it is also pursuing other options, such as asking Nasdaq for an extra compliance period, and that the board would only consider the reverse split if those other options fail to resolve the issue.¹